Atai Life Sciences N.V.

NasdaqGM:ATAI Stock Report

Market Cap: US$219.8m

Atai Life Sciences Future Growth

Future criteria checks 2/6

Atai Life Sciences is forecast to grow earnings and revenue by 33.9% and 78.1% per annum respectively. EPS is expected to grow by 48.6% per annum. Return on equity is forecast to be -50.8% in 3 years.

Key information

33.9%

Earnings growth rate

48.6%

EPS growth rate

Pharmaceuticals earnings growth23.6%
Revenue growth rate78.1%
Future return on equity-50.8%
Analyst coverage

Good

Last updated15 Aug 2024

Recent future growth updates

Recent updates

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Jul 15
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

ATAI: Enormous Potential Upside But No Clarity Yet

May 27

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

Atai Life Sciences: Decentralized Drug Discovery Platform

Oct 06

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

Aug 15

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Jul 07

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Jun 30

Atai Life Sciences N.V.: A First Take

Jun 02

Atai Life Sciences And The Future Of Psychedelics For Mental Health

May 27

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Apr 22
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqGM:ATAI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202631-128-145-1426
12/31/20250-135-118-1306
12/31/20240-130-91-895
6/30/20240-58-79-79N/A
3/31/20240-34-86-86N/A
12/31/20230-40-85-84N/A
9/30/20230-67-93-93N/A
6/30/20230-145-104-102N/A
3/31/20230-149-103-102N/A
12/31/20220-152-105-104N/A
9/30/20220-196-97-94N/A
6/30/20221-194-96-95N/A
3/31/20220-205-73-71N/A
12/31/202120-168-65-63N/A
9/30/202120-166-50-49N/A
6/30/202120-218-27-26N/A
3/31/202120-185-34-33N/A
12/31/2020N/A-170-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATAI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATAI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATAI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATAI's revenue (78.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ATAI's revenue (78.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATAI is forecast to be unprofitable in 3 years.


Discover growth companies